Also interesting links about this compounds safety and effect as a treatment to Alzheimer&#x27;s disease that was previously published (<a href="http:&#x2F;&#x2F;www.alzres.com&#x2F;content&#x2F;5&#x2F;3&#x2F;25" rel="nofollow">http:&#x2F;&#x2F;www.alzres.com&#x2F;content&#x2F;5&#x2F;3&#x2F;25</a>)<p>Summary from that paper:
J147 is an exciting new compound that is extremely potent, safe in animal studies and orally active. J147 is a potential AD therapeutic due to its ability to provide immediate cognition benefits, and it also has the potential to halt and perhaps reverse disease progression in symptomatic animals as demonstrated in these studies.<p>---
The new paper is at:
<a href="http:&#x2F;&#x2F;www.impactaging.com&#x2F;papers&#x2F;v7&#x2F;n11&#x2F;pdf&#x2F;100838.pdf" rel="nofollow">http:&#x2F;&#x2F;www.impactaging.com&#x2F;papers&#x2F;v7&#x2F;n11&#x2F;pdf&#x2F;100838.pdf</a><p>Abstract:
Because age is the greatest risk factor for sporadic Alzheimer’s disease (AD), phenotypic screens based upon
old age‐associated brain toxicities were used to develop the potent neurotrophic drug J147. Since certain aspects of aging
may be primary cause of AD, we hypothesized that J147 would be effective against AD‐associated pathology in rapidly
aging SAMP8 mice and could be used to identify some of the molecular contributions of aging to AD. An inclusive and
integrative multiomics approach was used to investigate protein and gene expression, metabolite levels, and cognition in
old and young SAMP8 mice. J147 reduced cognitive deficits in old SAMP8 mice, while restoring multiple molecular markers
associated with human AD, vascular pathology, impaired synaptic function, and inflammation to those approaching the
young phenotype. The extensive assays used in this study identified a subset of molecular changes associated with aging
that may be necessary for the development of AD.